201000008937 atopic dermatitis Diseases 0.000 claims description 14.206010012601 Diabetes mellitus Diseases 0.000 claims description 14.206010012438 Dermatitis atopic Diseases 0.000 claims description 14.200000000018 inflammatory disease Diseases 0.000 claims description 16.MDEJZZIXATWVCP-UHFFFAOYSA-N O=C(c1cccnc1)NCc(cc1)ccc1-c1nc(ccc(Cl)c2)c21 Chemical compound O=C(c1cccnc1)NCc(cc1)ccc1-c1nc(ccc(Cl)c2)c21 MDEJZZIXATWVCP-UHFFFAOYSA-N 0.000 claims description 17.UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 34.150000002367 halogens Chemical class 0.000 claims description 52.229910052736 halogen Inorganic materials 0.000 claims description 52.229910052739 hydrogen Inorganic materials 0.000 claims description 66.239000011780 sodium chloride Substances 0.000 claims description 76.239000008194 pharmaceutical composition Substances 0.000 claims description 76.125000000217 alkyl group Chemical group 0.000 claims description 118.125000003118 aryl group Chemical group 0.000 claims description 168.108010064862 Nicotinamide Phosphoribosyltransferase Proteins 0.000 title abstract description 28.102000015532 Nicotinamide Phosphoribosyltransferase Human genes 0.000 title abstract description 28.239000000203 mixture Substances 0.000 title abstract description 81.230000002401 inhibitory effect Effects 0.000 title abstract description 85.150000001875 compounds Chemical class 0.000 title claims abstract description 316.Assignors: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY Publication of US20200247795A1 publication Critical patent/US20200247795A1/en Application granted granted Critical Publication of US11078195B2 publication Critical patent/US11078195B2/en Status Active legal-status Critical Current Adjusted expiration legal-status Critical Links ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HAN, GYOON HEE, KIM, HYUN SEOK Assigned to CHECKMATE THERAPEUTICS INC. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) Filing date Publication date Priority claimed from US201662309557P external-priority Application filed by Checkmate Therapeutics Inc filed Critical Checkmate Therapeutics Inc Priority to US16/085,774 priority Critical patent/US11078195B2/en Assigned to INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY reassignment INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Original Assignee Checkmate Therapeutics Inc Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.) ( en Inventor Hyun Seok Kim Gyoon Hee Han Current Assignee (The listed assignees may be inaccurate.
Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.) Active, expires Application number US16/085,774 Other versions US20200247795A1
#CHECKMATE THERAPEUTICS PDF#
Google Patents Compound for inhibiting nicotinamide phosphoribosyltransferase and composition containing sameĭownload PDF Info Publication number US11078195B2 US11078195B2 US16/085,774 US201716085774A US11078195B2 US 11078195 B2 US11078195 B2 US 11078195B2 US 201716085774 A US201716085774 A US 201716085774A US 11078195 B2 US11078195 B2 US 11078195B2 Authority US United States Prior art keywords group chemical formula present compound cancer Prior art date Legal status (The legal status is an assumption and is not a legal conclusion. Google Patents US11078195B2 - Compound for inhibiting nicotinamide phosphoribosyltransferase and composition containing same US11078195B2 - Compound for inhibiting nicotinamide phosphoribosyltransferase and composition containing same
0 kommentar(er)
